Literature DB >> 24789692

Varicella zoster immune status in children treated for acute leukemia.

Soonie R Patel1, Jessica Bate, Peter A C Maple, Kevin Brown, Judith Breuer, Paul T Heath.   

Abstract

Children treated for acute leukemia are at increased risk of severe infection with varicella zoster virus (VZV). We studied the VZV sero-status of children with acute leukemia prior to starting chemotherapy and after completion of chemotherapy. VZV sero-status was assessed using time resolved fluorescence immunoassay (TRFIA) before starting treatment and 6 months after completion of treatment. Prior to starting treatment for acute leukemia, a significant proportion of children (35%) are VZV seronegative. On completion of treatment most patients maintained protective VZV antibody levels; however, 35% had reduced/loss VZV antibody to a level considered non-protective and susceptible to VZV infection.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  acute leukemia; children; immunity; varicella zoster virus

Mesh:

Substances:

Year:  2014        PMID: 24789692     DOI: 10.1002/pbc.25086

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  3 in total

Review 1.  Progress in Treatment of Viral Infections in Children with Acute Lymphoblastic Leukemia.

Authors:  Maria Moschovi; Maria Adamaki; Spiros A Vlahopoulos
Journal:  Oncol Rev       Date:  2016-06-30

2.  Clinical characteristics and outcomes of varicella zoster virus infection in children with hematologic malignancies in the acyclovir era.

Authors:  Seul-Ki Kim; Min Chae Kim; Seung Beom Han; Seong Koo Kim; Jae Wook Lee; Nack-Gyun Chung; Bin Cho; Dae Chul Jeong; Jin Han Kang; Hack-Ki Kim
Journal:  Blood Res       Date:  2016-12-23

3.  The Impact of Chemotherapy after Pediatric Malignancy on Humoral Immunity to Vaccine-Preventable Diseases.

Authors:  Chiara Garonzi; Rita Balter; Gloria Tridello; Anna Pegoraro; Manuela Pegoraro; Monia Pacenti; Novella Scattolo; Simone Cesaro
Journal:  Mediterr J Hematol Infect Dis       Date:  2020-03-01       Impact factor: 2.576

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.